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Abstract
Aim American and European associations of cardiology published specific guidelines about recommended drugs for sec-
ondary prevention in ST-segment elevation myocardial infarction (STEMI) patients. Our aim was to assess whether drug 
prescription for STEMI patients was in accordance with the guidelines at discharge and after 1 year.
Method We used data of 361 patients admitted for STEMI in a tertiary hospital in Switzerland from 2014 to 2016. We 
assessed the adequacy of prescription of recommended drugs at two time points: discharge and after 1 year. Medications 
assessed were aspirin, P2Y12 inhibitors, statin, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor 
blockers (ARBs) and β-blockers. We took into account several criteria like statin dosage (low versus high intensity) and pres-
ence of contraindication for consideration of optimal therapy. Predictors of incomplete prescription of guideline medications 
were then assessed with multivariate logistic regression models.
Results From discharge (n = 358) to 1-year follow-up (n = 303), rate of optimal prescription was reduced from 98.6 to 
91.7% for aspirin, from 93.9 to 79.1% for P2Y12 inhibitors, from 83.8 to 65.7% for statins, from 98.6 to 95.6% for ACEIs/
ARBs, and from 97.1 to 96.9% for β-blockers. Predictors of incomplete prescription of guideline medications at discharge 
were female sex (odds ratio [OR] 2.54, p = 0.007), active or former smoker status (OR 2.29, p = 0.017), multivessel disease 
(OR 2.07, p = 0.022), left ventricular ejection fraction < 40% (OR 2.49, p = 0.008), and transfer to cardiac surgery (OR 9.66, 
p = 0.018). At 1 year, age > 65 (OR 1.92, p = 0.036) remained the only significant predictor.
Conclusion The present study showed a high prescription rate of guideline-recommended medications in a referral center 
for primary percutaneous coronary intervention. At discharge, women and co-morbid patients were at the highest risk of 
incomplete prescription of guideline medications, whereas long-term prescription was suboptimal for elderly. A drug lacking 
at time of discharge was rarely introduced within the year, which underscores the paramount importance of optimal prescrip-
tion at time of discharge. Strategies like implementing a standardized prescription could reduce the proportion of suboptimal 
prescription. It could therefore be one way to improve the long-term quality of care of our patients to the highest level. This 
study used local data from AMIS Plus—National Registry of Acute Myocardial Infarction in Switzerland (NCT01305785).
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1 Introduction
Acute coronary syndrome (ACS) remains a leading cause 
of morbi-mortality in developed countries [1, 2]. Among 
the three types of ACS [ST-segment elevation myocardial 
infarction (STEMI), non-ST-elevation myocardial infarction 
(NSTEMI) and unstable angina (UA)], STEMI leads to the 
highest rate of death over the short term [3, 4]. Moreover, 
survivors of a first event remain at increased risk for subse-
quent cardiovascular events such as death, recurrent myocar-
dial infarction (MI), heart failure, arrhythmia, angina, and 
stroke [5]. Thus, secondary prevention has become increas-
ingly important in the care of STEMI patients.
Effective secondary prevention measures include partici-
pation in a cardio-rehabilitation program, lifestyle modifi-
cation, and use of a chronic cardioprotective drug regimen. 
Several randomized controlled studies have shown that use 
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Key Points 
The prescription rate of recommended drugs for the 
secondary prevention of acute coronary syndrome (ACS) 
has become a criterion to assess the quality of care in 
hospitals around the world. We found an optimal pre-
scription rate of 74.3% at discharge in a tertiary hospital 
in Switzerland, which is higher than most results from 
other ACS registries.
The most important finding of our study is that adher-
ence to guideline-recommended prescriptions decreased 
within the first year after ACS. We showed that this 
reduction was mostly due to a decrease in the dose of 
statin and early discontinuation of P2Y12 inhibitor. We 
also demonstrated that a drug which is lacking at the 
time of discharge without contraindication was rarely 
prescribed by general practitioners within the year.
These findings highlight the paramount importance 
of prescriptions at the time of hospital discharge. It is 
critical to focus on populations at increased risk of not 
receiving guideline-recommended medications and 
implement a standardized prescribing protocol for ACS 
patients at hospital discharge.
ACEI or ARB if the patient has a left ventricular ejection 
fraction (LVEF) below 40% and the prescription of BBs 
[17]. Schiele et al., who suggested some quality indicators 
for AMI, included the prescription of a high dose of statin 
as a quality indicator for secondary prevention [18]. In an 
era where hospital performance is measured with quality 
indicators, it is essential to evaluate the prescription pattern 
of our hospitals.
Therefore, to add knowledge about the quality of care in 
developed countries, we conducted a single-center study in a 
Swiss tertiary hospital with percutaneous intervention (PCI) 
facilities and sought to ascertain whether guideline-recom-
mended drugs were prescribed to STEMI patients. To fill the 
gaps of many studies about optimal prescription after ACS, 
we not only assessed prescription at discharge but also after 
1 year. Information on long-term prescription is essential to 
evaluate the quality of care of ACS patients. With these data, 
our objective was first to assess the quality of prescriptions 
and then to identify characteristics of patients who were less 
likely to receive an optimal prescription. Our final goal was 
to suggest a solution to enhance the quality of prescriptions 
which could be adapted for use in other developed countries.
2  Methods
This study was a prospective observational study that 
assessed prescription of medication for STEMI patients at 
the time of discharge from a tertiary university hospital and 
after a 1-year period. We also had access to the discharge 
letters and discharge prescriptions from the files of patients 
transferred to a regional hospital after PCI.
The study was approved in 2005 by the local ethics com-
mittee as part of the national AMIS Plus registry, which is a 
national prospective registry of patients with ACS admitted 
to participating hospitals in Switzerland. The Centre Hospi-
talier Universitaire Vaudois (CHUV) has been considered a 
local center since 2005, and all data used in this study were 
obtained from the local database.
2.1  Patient Population
Patients were screened during the period from April 15, 
2014 through April 15, 2016. Patients aged ≥ 18 years and 
diagnosed with STEMI were included if they had capacity 
for discernment and provided written consent. Diagnosis of 
STEMI required clinical signs of characteristic retrosternal 
pain for < 12 h and electrocardiography showing ST-segment 
elevation in more than two contiguous derivations, a new 
bundle branch block, or ST-segment depression ≥ 0.5 mm 
in the V1–V3 leads.
After screening, we excluded patients with a final diagno-
sis other than STEMI (e.g., NSTEMI, Takotsubo syndrome, 
and continued use of recommended drugs after an ACS are 
associated with improved clinical outcomes and decreased 
risk for complications [6, 7]. Current guidelines from the 
European Society of Cardiology (ESC) and the American 
College of Cardiology/American Heart Association (ACCF/
AHA) recommend a drug regimen for long-term therapy for 
STEMI patients undergoing percutaneous coronary interven-
tion (PCI). This drug regimen includes lifelong aspirin and 
high-intensity statin, in addition to a P2Y12 inhibitor for up 
to 1 year. Depending on the guidelines, a β-blocker (BB) 
and an angiotensin-converting enzyme inhibitor (ACEI) or 
angiotensin receptor blocker (ARB) are recommended in 
specific conditions [8–12].
A recent French study with more than 5000 STEMI 
patients showed that around 40% of STEMI patients were 
undertreated [13]. This had clinical consequences, as under-
treated patients had significantly higher 1-year mortality. 
In Switzerland, a few studies have already evaluated drug 
prescription for ACS patients at discharge, and one study 
assessed prescription over the long term [14–16]. All these 
studies showed a high adherence to guidelines, but none of 
them assessed statin intensity and the specific P2Y12 inhibi-
tor prescribed, which are also important factors for optimal 
drug prescription assessment. Quality measures defined by 
the AHA for acute myocardial infarction (AMI) include the 
prescription of aspirin at hospital discharge, the use of an 
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pericarditis, Prinzmetal angina), those with communication 
issues (e.g., inability to speak French or English, difficulties 
with elocution), those with a lack of capacity for discern-
ment, and patients lacking consent for participation. Patients 
anticipated to be not reachable after 1 year (e.g., patients 
who did not live in Switzerland or who were homeless) were 
also excluded.
2.2  Data Analysis
Clinical research nurses screened all patients admitted 
for STEMI and met them once screened. The nurses were 
dedicated to clinical research and did not work as nurses in 
the cardiac unit. If the patient agreed to participate in the 
study, nurses prospectively collected baseline data including 
general information (age, sex, weight, and height), previ-
ous adverse drug event, allergies, intolerance to drugs, lab 
values, cardiovascular risk factors, comorbidities, diagno-
sis, therapeutic strategy with drug prescriptions, and dis-
charge information (including discharge drug prescription). 
About 1 year after PCI, a clinical research nurse or a clinical 
research pharmacist contacted each participant by phone to 
collect data related to participation in cardio-rehabilitation, 
lifestyle changes, and current medical care (including all 
medication prescribed, with doses).
2.3  Outcomes
The primary outcome was the adequacy of prescription at 
discharge and at 1 year. Each drug category was defined as 
optimal or non-optimal prescription according to the follow-
ing criteria: aspirin for all patients, ticagrelor or prasugrel as 
a P2Y12 inhibitor [or clopidogrel if concomitant prescrip-
tion of oral anticoagulant (OAC) or high risk of bleeding], 
high-dose statin (e.g., atorvastatin 40–80 mg, rosuvastatin 
20–40 mg), BB if the patient had post-AMI LVEF < 40%, 
and ACEI/ARB if the patient had LVEF < 40% or diabetes. 
This implies that the non-prescription of a BB to a patient 
with LVEF ≥ 40% was considered as optimal, as well as the 
non-prescription of an ACEI/ARB to a patient without dia-
betes nor reduced LVEF.
The same criteria were used for assessment at the 1-year 
follow-up. However, duration of dual antiplatelet therapy 
(DAPT) with aspirin and a P2Y12 inhibitor for ≥ 12 months 
was required for consideration as optimal therapy. We 
included reason for non-prescription in our analysis at dis-
charge, and we presented results as adjusted prescription 
rate. Reasons for non-prescription accepted were history of 
life-threatening bleeding for aspirin, hypotension (systolic 
blood pressure < 100 mmHg) or acute renal failure (based 
on Kidney Disease: Improving Global Outcomes [KDIGO] 
criteria [19]) for ACEI/ARB, bradycardia (< 50 beats/min), 
second- or third-degree atrio-ventricular block, hypotension 
for BB, history of life-threatening bleeding, coagulopathy 
or thrombocytopenia for P2Y12 inhibitor (and prior stroke 
or age ≥ 75 years for prasugrel) and history of myopathy, 
rhabdomyolysis or severe hepatic impairment (transaminase 
elevation of more than twofold the highest normal value) for 
statins. Reasons for non-prescription were assessed with the 
discharge letter.
At 1 year, we asked for the complete medication regimen 
of the patient to assess if any OAC [vitamin K antagonist 
(VKA) or direct oral anticoagulant (DOAC)] had been pre-
scribed during the follow-up. In the case of an OAC intro-
duction, switch from ticagrelor to clopidogrel within the 
year was considered as optimal. During the phone interview 
with the patient, we asked him to look at his drug boxes and 
to read what was written on the boxes (drug name, dose). 
If the patient was not able to give the complete name of the 
drug or the dose (for example, if he was not at home at the 
time of the phone call), we called the prescriber or the phar-
macy to obtain the complete information.
Secondary outcomes were readmission within the follow-
up. Readmission and readmission reasons were assessed via 
a conversation with the patient at the time of the follow-up 
call. At the time of follow-up, we also checked for any read-
missions in the electronic patient record and collected this 
information from the regional hospital.
2.4  Statistical Analysis
Descriptive statistics considered frequencies and percentages 
for categorical variables, and mean value and standard devia-
tion (SD) for continuous variables. Rates of complete versus 
incomplete prescription of guideline medications at discharge 
were compared using the Chi square test for equal propor-
tions for categorical variables and the two-sample Student’s t 
test for equal means for continuous variables. Factors associ-
ated with incomplete prescription of guideline medications 
were further investigated with univariate and multivariate 
logistic regression models. Unadjusted odds ratios (ORs) 
and adjusted odds ratios  (ORadj) were estimated together 
with 95% confidence intervals (CIs). Candidate predictors 
included sex, age > 65 years, body mass index (BMI) > 25 kg/
m2, cardiovascular risk factors (active or former smoker, dys-
lipidemia, diabetes, and hypertension), comorbidity (yes/no), 
creatinine > 110 µmol/L, LVEF < 40%, transfer to a cardiac 
surgery service, and previous episodes of AMI, coronary 
artery bypass graft (CABG), or multivessel coronary disease. 
All factors were added to the multivariate model. A similar 
strategy was used to study prescription adherence to guide-
lines after 1 year. The selection of the criteria was based on 
known influencers from literature and on results from uni-
variate analyses. All statistics were computed using STATA 
version 14 (Stata Corporation, College Station, TX). All tests 
were two-tailed, with significance set at p < 0.05.
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3  Results
3.1  Study Population and Baseline Characteristics
The flowchart of patients included during the study period is 
presented in Fig. 1, whereas baseline characteristics of the 
361 patients included in the study are presented in Table 1.
The subgroup of 43 patients lost to follow-up was signifi-
cantly younger than the group of patients ultimately included 
in the study (46.5% were aged < 55 years, p = 0.02). None 
of the other baseline characteristics differed between groups 
(see Table S1 in the electronic supplementary material). For 
the 12 patients who died during follow-up, reasons for death 
were mainly unknown, and we did not have access to their 
current drug regimen soon before death. Patients who died 
during the 1-year study period were significantly older and 
overweight and more likely to have diabetes, hypertension, 
or plurivessel coronary disease. Prescriptions at discharge 
were not statistically different between patients who sur-
vived at 1 year and those who died within the study period 





- No STEMI, N=120
- No consent, N=116











- Not reachable N=43
Patients included for 
the whole one-year 
study
N=303
Fig. 1  Flow-chart of patients included from April 15, 2014 through 
April 15, 2016. STEMI ST-segment elevation myocardial infarction
Table 1  Baseline characteristics of study participants
Variables Frequency (%)
Overall (n = 361)
Demographic (n = 361)
Women 87 (24.1)
 Age, years (mean (SD)) 63.9 (13.1)
 Age group
 < 55 yr 95 (26.3)
 55–64 yr 95 (26.3)
 65–74 yr 95 (26.3)
 > 75 years 76 (21.1)
BMI categories (n = 360)
< 25 kg/m2 135 (37.5)
25–29.9 kg/m2 150 (41.7)
≥ 30 kg/m2 75 (20.8)
Cardiovascular risk factors
Smoking categories (n = 357)
 Active smoker 138 (38.7)
 Former smoker 102 (28.6)
 Non-smoker 117 (32.8)
Family history of CAD (n = 323) 97 (30.0)
History of hypertension (n = 361) 162 (44.9)
History of dyslipidemia (n = 355) 215 (60.6)
History of diabetes mellitus (n = 359) 53 (14.8)
Medical history
Prior AMI (n = 359) 47 (13.1)






Primary angioplasty 352 (97.5)
CABG 5 (1.4)
Conservative treatment 4 (1.1)
Involved artery (n = 361)
Right coronary artery 215 (59.6)
Interventricular artery 263 (72.9)
Left circumflex artery 158 (43.8)
Ramus angularis artery 5 (1.4)






3 or more 34 (9.4)
Post-PCI intervention before discharge (n = 361)
CABG 7 (1.9)
Pacemaker implantation 3 (0.8)
ICD implantation 3 (0.8)
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3.2  Adherence to Guidelines
Figure 2 shows the adequacy of prescription of each recom-
mended drug class at discharge and at 1-year follow-up. At 
discharge, rates of optimal prescription were > 90% for all 
drug classes except statin. After 1 year, this proportion was 
reduced for each class, but the decrease in magnitude was 
greatest for P2Y12 inhibitors and statins.
3.3  Prescription Rate of BB and ACEI/ARB According 
to LVEF
Figure 3 illustrates the proportion of patients receiving 
an ACEI/ARB or a BB according to LVEF. The propor-
tion of patients receiving ACEI/ARB and/or BB was high, 
with > 75% of patients receiving the drug at discharge and 
at 1 year. The differences within the groups LVEF ≥ 40% 
versus LVEF < 40% was not statistically significant. The rate 
of BB withdrawal from discharge to 1 year was 13.1% in the 
LVEF ≥ 40% subgroup (26 from 198 patients) and 8.3% in 
the LVEF < 40% subgroup (four from 48 patients). Reasons 
for withdrawal were side effect for four participants (13.3%), 
non-adherence for two participants (6.7%) and unknown for 
the remaining ones (24/30; 80%). For ACEI/ARB, the rate of 
withdrawal was 16% in the LVEF ≥ 40% subgroup (36 from 
225 patients) and 11.5% in the LVEF < 40% subgroup (six 
from 52 patients). Reasons for withdrawal were side effect 
(hypotension, cough, tiredness) for eight patients (19.0%), 
non-adherence for two patients (4.8%) and unknown for the 
remaining participants (76.2%).
3.4  Changes Within the Year
Changes in drug regimen within the year are presented in 
Table 2. The proportion of patients discharged with an opti-
mal prescription and for whom a change within the year 
resulted in a suboptimal prescription was as follows: 7.4% 
for aspirin, 17.5% for P2Y12 inhibitor, 25.6% for statin, 4.1% 
for ACEI/ARB, and 1.4% for BB. Reasons for these changes 
were drug withdrawal within the year for aspirin, ACEI/ARB 
and BB. Different reasons explained changes from optimal 
prescription at discharge to suboptimal prescription at 1 year 
for P2Y12 inhibitors and statins: among 268 patients dis-
charged with an optimal prescription of P2Y12 inhibitor, 19 
patients (7.1%) discontinued the drug earlier than 1 year, 19 
(7.1%) were switched from ticagrelor to clopidogrel with-
out concomitant OAC prescription, nine (3.4%) discontinued 
OAC after discharge and were not switched from clopidogrel 
to ticagrelor or prasugrel. Reasons for early discontinuation 
or drug switch were side effects in 12 patients (dyspnea, 
bleeding), three had a planned surgery or dental procedure, 
two reported to be not taking their drug, and one patient 
had a high hemorrhagic risk. The reason was unknown for 
the remaining participants (n = 33). Reasons for changing 
statins were drug withdrawal or drug dose reduction within 
the year. Among 251 patients prescribed high-dose statin 
therapy at discharge (three patients from 254 with optimal 
statin therapy had a contraindication for statin therapy), 19 
Table 1  (continued)
Variables Frequency (%)
LVEF category (n = 349)
< 30% 13 (3.7)
30–40% 59 (16.9)
> 40% 277 (79.4)
Destination at discharge (n = 360)
Home 179 (49.7)
Peripheral hospital 172 (47.8)
Other in-hospital service 9 (2.5)
AMI acute myocardial infarction, BMI body mass index, CABG coro-
nary artery bypass grafting, CAD coronary artery disease, ICU inten-
sive care unit, PCI percutaneous coronary intervention, ICD implant-
able cardioverter defibrillator, LVEF left ventricular ejection fraction
Fig. 2  Rate of optimal pre-
scription at discharge for each 
drug class (n = 358 for aspirin, 
P2Y12 inhibitor and high-
intensity statin; n = 349 for 
ACEI/ARB; n = 347 for BB) 
and at 1 year (n = 303 for aspirin 
and statin; n = 282 for P2Y12; 
n = 297 for ACEI/ARB; n = 295 
for BB). ACEI angiotensin-con-
verting-enzyme inhibitor, ARB 
angiotensin receptor blocker, BB 





















Aspirin P2Y12 inhibitor High intensive stan ACEI/ARB β-blocker
Discharge One-year
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(7.6%) discontinued the drug and 46 (18.3%) received pre-
scriptions for decreased doses within the year. Reasons for 
discontinuation or drug reduction were side effect for 13 
patients (20.0%), patient refusal for six patients (9.2%), a 
low-density lipoprotein cholesterol (LDL-C) value in the 
target for two patients (3.1%), and unknown for the rest of 
the participants (67.7%).
Among patients with a suboptimal drug prescription at 
discharge, changes for an optimal prescription at 1 year were 
variable between drugs: an ACEI/ARB was introduced to 
80% of the patients and aspirin to 25% of them. Statins were 
introduced or up-titrated to a high-intensity dose in 20.4% 
of the population.
3.5  Proportion of Patients with an Optimal Drug 
Regimen According to Guidelines
At discharge, 266 patients had received an optimal drug 
regimen as recommended (74.3%). In the subgroup of 
patients with LVEF ≥ 40% (n = 276), 223 (80.8%) received 
an optimal drug regimen, significantly more often than in 
the subgroup of patients with LVEF < 40% (n = 71), 43 
(60.6%) (p < 0.001). After 1 year, the rate of optimal pre-
scription in the whole population decreased to 49.1% (135 
patients from 275 with complete data). Among patients with 
LVEF ≥ 40% (n = 225), 117 (52.0%) received an optimal 
drug regimen, whereas among patients with LVEF < 40% 
(n = 50), 18 (36.0%) received an optimal drug regimen. The 
difference between the two groups is statistically significant 
(p = 0.041).
3.6  Predictors of Incomplete Adherence 
to Guidelines
Predictors of incomplete adherence to guidelines at dis-
charge and at 1 year were further investigated using uni-
variate and multivariate logistic regression models (Table 3). 
The number of patients included in this table is lower than 
the whole collective of patients we had for the analysis. This 
discrepancy is due to missing data for some predictors (i.e., 
Fig. 3  Prescription rate of 
ACEI/ARB and BB at discharge 
and at 1 year, according to 
patient’s LVEF after STEMI. 
Eleven patients with unknown 
LVEF at discharge and eight 
at 1 year. ACEI angiotensin-
converting-enzyme inhibitor, 
ARB angiotensin receptor 
blocker, BB β-blocker, LVEF 
left ventricular ejection fraction, 



















ACEI/ARB β-blocker ACEI/ARB β-blocker
Discharge One-year
LVEF < 40% (n= 71 at discharge and 56 at one-year)LVEF ≥ 40% (n=276 at discharge and 239 at one-year)
Table 2  Drug changes within the year
a 21 patients had an unknown duration of P2Y12 inhibitor
b 3 patients had a contraindication for statins
c 6 patients with unknown LVEF
d 8 patients with unknown LVEF
Optimal prescription at 
discharge (n)
Suboptimal prescription 




at 1-year; n (%)
n n % n n %
Aspirin (n = 303) 299 22 7.4 4 1 25.0
P2Y12 inhibitor (n = 282a) 268 47 17.5 14 2 14.3
High intensive statin (n = 300b) 254 65 25.6 49 10 20.4
ACEI/ARB (n = 297c) 292 12 4.1 5 4 80.0
Beta-blocker (n = 295d) 287 4 1.4 8 3 37.5
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dyslipidemia, smoking status, etc.). For the 1-year analy-
sis, we had 21 patients missing data for the DAPT dura-
tion, which did not allow us to assess if the prescription was 
complete or incomplete. These patients were not taken into 
account in the analysis.
The univariate model showed that women, individuals 
aged > 65 years, patients with more comorbidities, patients 
with prior AMI, patients with LVEF < 40%, and patients 
with multivessel coronary disease were at increased risk 
for incomplete prescription of guideline medications at dis-
charge. The strongest predictor of incomplete prescription 
of guideline medications was transfer to cardiac surgery for 
CABG (OR 10.87, p < 0.005). Indeed, from nine patients 
transferred to cardiac surgery, only two of them had a com-
plete prescription of guideline medication at discharge, 
with P2Y12 inhibitor being the drug most often lacking. 
When all factors were entered together into a multivariate 
model, only female sex, active or former status as a smoker, 
LVEF < 40%, patients with multivessel disease, and patients 
transferred to cardiac surgery remained significantly associ-
ated with incomplete adherence to guidelines at discharge 
 (ORadj > 2.0).
The univariate model identified fewer significant pre-
dictors of incomplete prescription after 1  year, with 
age > 65  years, presence of a comorbidity, creatinine 
level > 110 µmol/L and LVEF < 40% being significant fac-
tors. When all factors were entered in a multivariate model, 
age > 65  years remained significantly associated with 
incomplete adherence to guidelines  (ORadj 1.92, p = 0.036). 
As all patients being transferred to cardiac surgery for 
CABG had an incomplete prescription after 1 year, this pre-
dictor could not be taken into account for the 1-year analysis.
3.7  Readmission
Among 301 patients with available data on readmission 
at 1 year, 73 (24.3%) were readmitted within the year; 53 
(17.6%) were readmitted for a cardiovascular event or a car-
diac procedure. Reasons for readmission are presented in 
Table S3 in the electronic supplementary material. Factors 
associated with emergency readmission for acute cardiovas-
cular disease were tested with univariate logistic regression 
models (see Table S4 in the electronic supplementary mate-
rial). Incomplete adherence to guidelines at discharge was 
not significantly associated with rate of readmission.
4  Discussion
We found high adherence to guidelines for the prescription 
of medications for STEMI patients. At discharge, 74.3% of 
patients had received an optimal drug prescription. After 
1 year, the percentage had decreased to 49.1%. These results 
are encouraging, but still show an incomplete implementa-
tion of secondary prevention drugs. The decrease in prescrip-
tion rate within the year was most apparent for prescriptions 
Table 3  Predictors of incomplete guideline adherence at discharge and after 1 year
Significant P values (< 0.05) are in bold
AMI acute myocardial infarction, BMI body mass index, CABG coronary artery bypass grafting, LVEF left ventricular ejection fraction, na not 
applicable
Incomplete prescription at discharge Incomplete prescription at 1 year
Univariate logistic regres-
sion (n = 352–358)
Multivariate logistic regres-
sion (n = 332)
Univariate logistic regres-
sion (n = 277–282)
Multivariate logistic regres-
sion (n = 261)
OR 95% CI P value ORadj 95% CI P value OR 95% CI P value ORadj 95% CI P value
Female sex 1.81 1.07–3.07 0.026 2.54 1.29–5.02 0.007 1.47 0.82–2.62 0.195 1.16 0.59–2.30 0.668
Age > 65 yr 2.27 1.39–3.69 0.001 1.22 0.64–2.33 0.541 2.61 1.60–4.28 0.000 1.92 1.04–3.53 0.036
BMI > 25 kg/m2 0.87 0.54–1.42 0.581 0.95 0.52–1.75 0.878 0.69 0.42–1.12 0.133 0.63 0.36–1.10 0.106
Active/former smoker 1.53 0.89–2.61 0.123 2.29 1.16–4.50 0.017 0.62 0.37–1.03 0.064 0.91 0.51–1.62 0.748
Dyslipidemia 0.79 0.49–1.29 0.353 0.75 0.41–1.39 0.368 1.12 0.68–1.83 0.662 1.10 0.62–1.94 0.741
Diabetes 1.21 0.63–2.34 0.557 0.61 0.26–1.47 0.276 0.74 0.36–1.53 0.424 0.56 0.24–1.32 0.185
Hypertension 1.57 0.97–2.52 0.065 1.08 0.57–2.05 0.818 1.34 0.83–2.17 0.230 0.96 0.53–1.75 0.904
Comorbidity present 1.71 1.05–2.78 0.030 1.34 0.74–2.45 0.337 1.88 1.12–3.17 0.017 1.70 0.94–3.08 0.078
Creatinine > 110 µmol/L 1.62 0.89–2.93 0.107 1.50 0.70–3.22 0.292 2.18 1.11–4.27 0.023 1.69 0.78–3.67 0.185
Prior AMI 2.19 1.16–4.16 0.016 1.66 0.73–3.76 0.228 1.39 0.68–2.82 0.365 1.32 0.57–3.05 0.513
Prior CABG 3.74 0.98–14.22 0.053 2.53 0.49–12.90 0.265 1.43 0.24–8.72 0.695 1.13 0.16–8.14 0.902
LVEF < 40% 2.74 1.56–4.81 0.000 2.49 1.27–4.85 0.008 1.93 1.02–3.63 0.043 1.70 0.83–3.48 0.148
Multivessel disease 2.40 1.42–4.05 0.001 2.07 1.11–3.86 0.022 0.92 0.57–1.48 0.718 0.71 0.41–1.23 0.225
Cardiac surgery transfer 10.87 2.22–53.32 0.003 9.66 1.46–63.75 0.018 1.00 na na 1.00 na na
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of statins and P2Y12 inhibitors, with many patients report-
ing side effects as the reason for decreasing the drug dose, 
discontinuation of the drug, or switching to another drug 
entirely. This result highlights that STEMI patients suffer 
from side effects more frequently than patients enrolled in 
clinical studies. Our results show the difficulty of following 
guidelines in a real-life setting over the long term. Moreover, 
we showed that a drug that is not optimally prescribed at the 
time of discharge is rarely introduced within the year by gen-
eral practitioners (GPs), except for ACEIs or ARBs. GPs are 
confident with the discharge prescription from specialists. 
These results show the importance of an optimal prescrip-
tion at discharge and are supported by the literature, which 
largely showed an effect of optimal prescription at discharge 
on 1-year mortality after STEMI [13, 20].
Our results were consistent with the finding of other reg-
istries in Switzerland with a general high rate of prescription 
of recommended drugs [14]. Compared to registries from 
other countries, we found a better optimal prescription rate 
at discharge and at 1 year [20, 21]. However, the results of 
registries are highly dependent on the method used to assess 
optimal drug prescription. A recent study conducted in the 
United States used the same method as we did (i.e., includ-
ing contraindication assessment and statin dose) and showed 
similar results to ours, with an unexpected high adherence to 
guidelines [22]. We must be very aware of the method used 
for the assessment of outcomes before benchmarking and 
assessing the quality of care.
Multivariate analysis showed that patients with incom-
plete prescription of guideline medications at the time of 
discharge were more likely to be women and individuals 
with comorbidities and reduced LVEF. We also found that 
transfer to cardiac surgery was the strongest predictor of 
incomplete prescription of guideline medication. This last 
result is explained by the reluctance of surgeons to prescribe 
DAPT after CABG. Despite the fact guidelines recommend 
the use of DAPT after ACS requiring CABG [8, 23], sur-
geons from our institution fear pericardial blood effusion 
after surgery, and DAPT is still a subject of discussion.
The difference in prescription rate at discharge between 
men and women is consistent with previous studies [24, 
25]. In our study population, we found that the disparity 
between men and women occurred mainly with the prescrip-
tion of statins, women receiving more often medium- or 
low-intensity statin therapy than men (24.7% vs 11.4% for 
men). The reasons for this gender disparity in the likelihood 
of receiving all recommended ACS prescriptions remain to 
be elucidated. Smolina et al. hypothesized that perceived 
risk for adverse outcomes after ACS is lower for young 
women because of a traditional school of thought dictating 
that cardiovascular disease is primarily a male disease [25]. 
However, clinical studies reported no difference by gender 
in terms of the safety or efficacy of any of the drugs after 
ACS, and women should receive the same intensity of statin 
therapy as men [6].
At 1 year, elderly patients (i.e., > 65 years) were more 
likely to have a suboptimal prescription. Older age is also 
already known as a risk factor for suboptimal prescription 
[24, 26–28]. We hypothesize that the disparity we found in 
our results is partly due to this perceived risk of MI recur-
rence and to the perceived risk of side effects, older patients 
being more likely to develop side effects due to polyphar-
macy [26]. However, Tomasevic et al. showed recently that 
the subgroup of older and comorbid patients with ACS ben-
efit from an optimal post-ACS treatment, with a reduction 
in the 1-year mortality [13].
Finally, our findings suggest that clinicians are less 
aggressive with women and more fragile patients (elderly, 
comorbid patients, patients with reduced LVEF) than with 
individuals with fewer co-morbidities. We must therefore 
remind prescribers of the unequivocal benefits of secondary 
prevention in all of the STEMI population and encourage the 
prescription of optimal therapy to all patients.
Another important finding of our study is that BBs and 
ACEIs/ARBs were largely prescribed in the whole STEMI 
population. In patients with preserved LVEF, we found 
that 83.3% of patients received a BB and 94.2% received 
an ACEI/ARB at hospital discharge. However, the system-
atic use of these two classes of drugs in a modern popula-
tion with a low prevalence of reduced ejection fraction is 
today questioned [29–31]. The reason is that studies proving 
their beneficial effects were conducted in the 1980s, prior 
to the implementation of new strategies of revasculariza-
tion and the use of potent antithrombotic drugs and statins 
[32–38]. Several observational studies tried to assess the 
efficacy of BBs in the population with preserved LVEF, but 
results were contradictory, some studies showing a beneficial 
impact [39–42] and others not [29, 30, 43, 44]. Unfortu-
nately, all these studies were based on registries with their 
known limitations. To this day, no randomized controlled 
trial has assessed the efficacy of BBs and ACEIs/ARBs for 
patients with preserved LVEF. As a consequence, current 
American and European guidelines still advocate the use of 
BBs and ACEIs/ARBs in all patients after STEMI, but with 
a class IIb level A and class IIa level A recommendation, 
respectively. The classes rise to I level A for patients with 
reduced LVEF [12, 45]. The high rate of ACEI/ARB pre-
scription in patients with preserved LVEF can be explained 
by the high prevalence of patients with hypertension, ACEI/
ARB being the first choice antihypertensive class post-AMI. 
BBs are also still widely prescribed, and the dose should in 
practice be up-titrated to the highest dose tolerated. This 
study does not address the doses of BB being prescribed, but 
we feel that they are often low and rarely up-titrated after 
discharge. This hypothesis could be addressed in a study 
dedicated to this subject. Therefore, the prescription of BB 
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with low doses to patients with preserved LVEF could be 
questioned. At this time, there is no clear evidence in favor 
of their systematic use in the long term. However, the fear 
of ventricular arrhythmias as a complication of STEMI stays 
a strong argument in favor of BB prescription in the post-
infarct period. We must now assess if BBs are still useful 
in the long term to reduce the morbi-mortality of STEMI 
patients. To drastically change the practice and have argu-
ments to stop their prescription, we are now waiting for 
large randomized controlled trials to answer this question. 
In the meantime, cardiologists will probably remain careful 
and continue to prescribe these drugs in the whole STEMI 
population.
4.1  Implication for Clinical Practice
Although our study was conducted in a tertiary hospital and 
cannot be generalized to all centers, we were able to show 
that the prescription of an optimal medication regimen at 
discharge for STEMI patients was achievable. We reached 
a very high level of optimal prescription compared to other 
registries. In Switzerland, practitioners are in general disci-
plined to follow guidelines. Additionally, Switzerland is a 
small country with a highly developed healthcare system; 
information is then easily passed through different hospi-
tals. Nevertheless, in modern healthcare, quality of care is 
becoming increasingly important, and our scope would be 
to reach a 100% rate of optimal prescription. Therefore, to 
reach a 100% rate of prescription at discharge, we plan to 
introduce a standardized prescription for all STEMI patients, 
with a reason for nonprescription being mandatory in the 
discharge letter. This will automatically reduce the rate of 
suboptimal prescription at discharge, and it will also give 
information to the GP about the reason for the lack of a 
medication. This will then allow the GP to rethink the whole 
prescription over the long term and reduce the rate of sub-
optimal prescription.
4.2  Limitations and Bias
The major limitation of our study is the small study popu-
lation. Our hospital is a referral center in a small part of 
Switzerland. However, this study will allow centers to make 
a benchmark for quality of care of STEMI patients.
Another limitation of our study is the presence of a recall 
bias. We assessed the prescriptions provided at 1-year fol-
low-up with a call to the patient, rather than the prescriber. 
Patients were asked to report on the previous 1-year period 
and likely provided incomplete information. We tried to 
minimize this phenomenon by asking patients to read what 
was written in their drug packages or by contacting the phy-
sician when the patient had any doubt about the accuracy of 
their reporting. Reasons for non-prescription at 1 year were 
also difficult to assess. Patients did not know reasons for 
a drug withdrawal from their practitioner, which resulted 
in a lot of unknown reasons in our results. Selection bias 
may also have colored the results presented above, suggested 
by a higher proportion of young patients that were lost to 
follow-up. Younger patients being not retired have less time 
to devote to support of a clinical study.
5  Conclusion
The present results provided information about the care pro-
vided for STEMI patients in a real-life clinical setting. The 
data collected showed that recommended medications were 
prescribed with high frequency at discharge (74.3%) and 
decreased at 1 year (49.1%). We also showed that patients 
most likely to receive a suboptimal prescription were 
women, elderly, and patients with comorbidities. We must 
therefore attempt to reduce the frequency of prescription 
errors at the time of discharge and implement a standardized 
prescription for all patients. Establishing such preventive 
measures should improve the quality of care provided to 
STEMI patients.
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